| Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity |
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension |
globenewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT) |
NEW YORK , May 5, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Inhibikase Therapeutics, Inc. (NASDAQ: IKT) on behalf of the company's shareholders. The investigation seeks to determine whether Inhibikase Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2025-05-05 12:30:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer |
BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025. “David has extensive experience in financial strategy and corporate governance, as well as an established reputation within the life sciences capital markets sector, and we are thrilled to welcome him as our new Chief Financial Officer,” said Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics. |
globenewswire.com |
2025-04-14 12:00:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity |
New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension |
globenewswire.com |
2025-03-27 18:01:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now |
Inhibikase Therapeutics (IKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2025-03-05 12:56:20 |
Czytaj oryginał (ang.) |
| Inhibikase Announces Expansion of Senior Leadership Team |
--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension (“PAH”) to its senior leadership team. Chris Cabell, M.D. |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth |
-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief Executive Officer, replacing Dr. Milton H. Werner, founder of Inhibikase, effective February 14, 2025. |
globenewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study |
Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating and walking in a mid-stage study. |
reuters.com |
2025-01-29 20:30:34 |
Czytaj oryginał (ang.) |
| Inhibikase: Potential To Improve Current Treatment Options For PAH Patients |
The company received FDA approval to initiate a late-stage study of IKT-001Pro for pulmonary arterial hypertension, backed by $275 million in funding. IKT-001Pro, a modified version of imatinib, aims to treat PAH with fewer side effects, leveraging Inhibikase's RAMP drug innovation engine. Risvodetinib, targeting untreated Parkinson's Disease, is in a phase 2 study with top-line data expected in Q4 2024, presenting a catalyst opportunity. |
seekingalpha.com |
2024-11-19 15:32:35 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity |
-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension -- |
globenewswire.com |
2024-11-14 10:37:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension |
-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the closing of a private placement of approximately $110 Million from the issuance and sale of shares of the Company's common stock and accompanying warrants with potential aggregate financing of up to approximately $275 Million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses. The financing will fund execution of the Phase 2b ‘702' trial in Pulmonary Arterial Hypertension (PAH) and for general corporate purposes. |
globenewswire.com |
2024-10-21 13:05:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension |
-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the pricing of an approximately $110 million private placement financing, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement to finance the initiation of a Phase 2b trial in pulmonary arterial hypertension (“PAH”) and for general corporate purposes. |
globenewswire.com |
2024-10-09 13:18:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript |
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q2 2024 Earnings Conference Call August 15, 2024 8:00 AM ET Company Participants Alexander Lobo - Precision AQ, Investor Relations Milton Werner - President and Chief Executive Officer Garth Lees-Rolfe - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group Edward White - H.C. Wainwright Operator Greetings and welcome to the Inhibikase Therapeutics Second Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-08-15 22:13:09 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity |
BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the second quarter ended June 30, 2024 and highlighted recent developments. “The first half of 2024 has showcased the strength of our pipeline through the continued execution of key milestones for both risvodetinib (risvo) and IkT-001Pro,” said Dr. Milton H. |
globenewswire.com |
2024-08-14 20:25:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 |
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 15, 2024, to provide a corporate update and review the financial results. |
globenewswire.com |
2024-08-07 12:00:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease |
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the company has completed enrollment in the Phase 2 ‘201' trial evaluating the safety and tolerability of risvodetinib (“risvo”), a potent selective c-Abl inhibitor, for treatment in untreated Parkinson's patients. The company expects to report trial results in the fourth quarter of 2024. |
globenewswire.com |
2024-06-17 12:05:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs |
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced expansion of its therapeutic pipeline and multiple updates to its Research and Development programs. “At Inhibikase we have let fundamental scientific discoveries drive identification of new product candidates that could transform the lives of patients. |
globenewswire.com |
2024-06-05 12:05:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million |
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered Series A warrants to purchase up to an aggregate of 1,672,452 shares of common stock, and unregistered Class B warrants to purchase up to an aggregate of 1,672,452 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold with one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock at a combined purchase price of $1.68. The Series A and Series B warrants will each have an exercise price of $1.68 per share, will be exercisable beginning on the effective date of stockholder approval and, in the case of Series A warrants, will expire on the one-year anniversary from the date of stockholder approval, and in the case of Series B warrants, will expire on the five-year anniversary from the date of stockholder approval. |
globenewswire.com |
2024-05-20 12:01:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript |
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q1 2024 Earnings Conference Call May 16, 2024 8:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Milton Werner - CEO Garth Lees-Rolfe - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Greetings and welcome to Inhibikase Therapeutics First Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-05-18 01:57:08 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity |
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET |
globenewswire.com |
2024-05-16 00:00:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement |
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (“SEC”) with respect to the withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-278844) that it filed with the SEC originally on April 19, 2024. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement. |
globenewswire.com |
2024-05-15 12:45:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension |
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – |
globenewswire.com |
2024-05-09 12:00:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs |
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders. |
globenewswire.com |
2024-04-18 20:30:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension |
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension |
globenewswire.com |
2024-04-03 12:05:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript |
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-28 19:13:08 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity |
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET |
globenewswire.com |
2024-03-27 18:15:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders |
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics, will present an update on the of the 201 Trial evaluating risvodetinib (“risvo”) at the 2024 AD/PD Meeting being held March 5-9, 2024 in Lisbon, Portugal. |
globenewswire.com |
2024-03-07 10:30:00 |
Czytaj oryginał (ang.) |
| Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro |
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate |
globenewswire.com |
2024-02-28 18:05:00 |
Czytaj oryginał (ang.) |